Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene - PubMed (original) (raw)

Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene

T Iwamoto et al. EMBO J. 1991 Nov.

Abstract

We generated four independent transgenic mouse lines that showed severe melanosis of the whole body by introducing the ret oncogene fused to the mouse metallothionein (MT)-I promoter-enhancer (MT/ret). Whereas melanogenesis was accelerated without distinct proliferative disorders in one line, melanocytic tumours frequently developed in the other three lines. Northern hybridization and in situ hybridization analyses showed that tumour cells and non-tumorous melanin-producing cells expressed the transgene at high levels. The aberrant melanogenesis and tumour development were influenced by genetic and environmental factors. Furthermore, crossbreeding experiments between the transgenic mice and Wv mice suggested that the ret gene product can partially compensate for the defect of melanocyte development in Wv mice. This is a novel mammalian model in which melanosis and melanocytic tumours develop stepwise, triggered by a single transgene.

PubMed Disclaimer

References

1. 1. Oncogene. 1989 Jun;4(6):805-6 - PubMed
2. 1. Oncogene. 1990 Sep;5(9):1291-6 - PubMed
3. 1. J Cell Biol. 1989 Dec;109(6 Pt 1):3115-28 - PubMed
4. 1. Anal Biochem. 1987 Apr;162(1):156-9 - PubMed
5. 1. EMBO J. 1987 Dec 20;6(13):4055-65 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)